Clinical Trial Update: PD-1 Antibody in Addition to BACE in Patients With NSCLC: A Randomised Controlled Trial [Phase 2, Phase 3]

View source ↗

Summary

A randomized trial evaluating a PD-1 antibody in addition to BACE in non-small cell lung cancer, spanning Phase 2 and Phase 3.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• BACE
• PD-1 antibody (PD-1 inhibitor)

Snippet

Sponsor: Xuhua Duan | Conditions: NSCLC | Phase 2, Phase 3 | Status: UNKNOWN